Signos Review

Signos+ verdict: a GLP-1 program with a glucose monitor baked in

Most telehealth weight-loss programs ship you a vial of semaglutide and leave you to figure out the rest. Signos+ does something genuinely different: it pairs clinician-prescribed compounded semaglutide with an FDA-cleared continuous glucose monitor (CGM) and a companion app, so you can actually see how your body responds to food, activity, and the medication in real time. If you're the kind of person who wants data — not just a weekly shot and a bathroom scale — this is one of the few programs built around that idea. If you just want the cheapest possible injection, it's not the obvious pick.

How the $199/month price actually works

Signos+ starts at $199 a month, but read the fine print: that rate is tied to a six-month program, not a casual month-to-month subscription. You're committing to the plan up front. The pitch the company leans on is that $199 is roughly what you'd pay for the medication alone elsewhere — and here the CGM and app come included at no extra charge. Whether that framing holds up depends on what you'd otherwise pay, but the math is at least honest: the glucose hardware isn't an upsell tacked onto the bill.

For reference, the category median for a program like this sits around $170 a month, so $199 is a bit above the middle of the pack on the headline number — though most of those cheaper programs don't hand you a continuous glucose monitor. Signos+ doesn't appear to run a discounted first-month teaser rate, so what you see is what you commit to.

• $199/month, billed as a six-month program (not month-to-month)
• CGM hardware and app access included — no separate device fee
• Free rapid shipping to your door
• HSA/FSA eligible, so pre-tax dollars can cover it

The medication: compounded semaglutide, dispensed through the program

The drug on offer is compounded semaglutide, the same active ingredient in Wegovy and Ozempic. The app's own dosing screen shows a weekly semaglutide ladder (for example, 0.50 mg weekly), which lines up with a standard titration schedule. Medication costs are folded into the program price — you're not paying for the shot separately — and supplies ship with it.

One honest caveat: tirzepatide is not shown anywhere in the program. If you specifically want tirzepatide, you'll need to confirm availability directly, because as it stands this is a semaglutide-only offering.

What actually sets Signos apart: glucose-guided weight loss

This is the whole reason Signos+ exists. Signos is, at its core, a metabolic-health company built around continuous glucose monitoring — and the GLP-1 medication is layered on top of that, not the other way around. The CGM streams your glucose response throughout the day, and the app translates it into coaching prompts: which meals spike you, how movement blunts a spike, how your numbers shift as the medication titrates up.

The practical payoff is twofold. While you're on the medication, you're learning the habits that drive your own metabolism instead of flying blind. And when you eventually taper off the GLP-1 — the moment most people regain weight — you already understand which foods and routines keep your glucose steady. That's a real differentiator, and it's the strongest argument for paying a little more than a bare-bones injection program.

Who should choose Signos+ — and who should skip it

Choose it if you're motivated by data, want to build durable habits rather than just lose weight on a drug, or you're managing blood-sugar concerns alongside weight. The CGM turns the program into a feedback loop, and for the right person that's worth real money.

Skip it if you want the lowest sticker price, you're not interested in wearing a sensor or checking an app, or you specifically need tirzepatide or a brand-name finished product. Also skip it if you're not ready to commit for six months — the headline rate assumes you are.

Trust, safety, and what isn't published

A few things land in the program's favor. The CGM is FDA-cleared hardware, the program is clinician-reviewed, and there are no FDA warning letters on file against it in our record. That's a cleaner trust profile than some compounding-heavy competitors.

But be clear-eyed about the gaps. Compounded GLP-1s are not FDA-approved finished products — they're mixed by a compounding pharmacy, and that carries different oversight than a branded vial. Signos also doesn't publish its compounding pharmacy partner or a clear list of states it serves on its landing page, which is information you'd ideally want before signing up. None of that is disqualifying, but it means you should confirm your state and ask who's filling the prescription before you commit. You can read how we weigh these factors in our scoring methodology.

Bottom line

Signos+ is a smart fit for one specific person: someone who wants to lose weight on a GLP-1 and genuinely use the experience to understand their own metabolism, with a glucose monitor and app doing the teaching. At $199 a month with the CGM included, the bundle is fairly priced for what it is. It's not the cheapest option, it's semaglutide-only, and it asks for a six-month commitment plus some missing transparency on pharmacy and states. But if the glucose-guided angle speaks to you, few programs do it better.

Worth pricing against RNK Health ($197/month) and Care Bare Rx ($199/month) before you commit — both sit close to Signos on cost and formulation.